Of course they do see the biomarkers in all the patient during the trial, including many of the top 20 CV biomarkers , using blood tests. MOCA scores as well, so they are seeing if there are a lot of improvement in some patients from baseline or not. They also know how many. These are all progressive diseases in a pretty sick population, and the data is blinded meaning neither patient nor Dr nor Company know who is on drug. But they all know if some patients biomarkers are improved and by how much. As for SOC the published trial protocol excludes participants with very high triglycerides; to me that would exclude most if not all taking Vascepa or Epanova from this trial so there is little if any SOC issue/ effect with them. All just my opinion of course, happy to be corrected  and enlightened.